IARAS

IRRAS AB – Q3 Report 2018 – invitation to conference call and webcast

On Thursday November 8, at 04.00 p.m. CET IRRAS will host a conference call and an online presentation of its Q3 2018 interim report (which is published the same day at 08.00 a.m. CET).

The dial-in numbers for the conference call are:

Sweden: +46 8 566 426 91 Rest of the world: +44 20 3008 9810

The presentation will also be webcast and can be accessed from the following web address: https://financialhearings.com/event/10811

Hosts: President CEO Kleanthis G. Xanthopoulos, Ph.D. and CFO and Deputy CEO Fredrik Alpsten

Investor and Media Contact:

Fredrik Alpsten CFO and Deputy CEO +46 706 67 31 06 fredrik.alpsten@irras.com

About IRRAS

IRRAS AB (Nasdaq First North Premier: IRRAS) is a publicly-traded, commercialstage medical technology company focused on developing and commercializing innovative solutions for brain surgery. The company's initial product, IRRA*flow®*, addresses the complications associated with the current methods of managing intracranial fluid by using a dual lumen catheter that combines active irrigation with ongoing fluid drainage. IRRA*flow* received FDA clearance in July 2018.

Regularly during treatment, the IRRA*flow* catheter is automatically flushed to prevent common catheter occlusions from forming. Because IRRA*flow* is a completely closed system, it is designed to reduce the documented infection risk of these procedures. Additionally, IRRA*flow* incorporates ICP monitoring and uses a proprietary software to regulate treatment based on desired pressure levels.

With its unique product portfolio, protected by property patents and patent applications, IRRAS is well positioned to establish a leadership position in the medical device market. IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in Munich, Germany, and San Diego, California, USA. For more information, please visit <u>www.irras.com</u>